Skip to main content
Premium Trial:

Request an Annual Quote

Mary Schramke, Kevin Corcoran, Friedrich von Bohlen, Thure Etzold, Peter Willinger, Joseph Donahue, Michael Pellini, Norrie Russell, Bjrn Ekstrm, Tim Germann

Premium

Lynx Therapeutics has named Mary Schramke as acting CEO, effective Dec. 15. She succeeds Kevin Corcoran, Lynx’s current president, CEO, and director, who is leaving to pursue “another business opportunity,” according to the firm. Lynx shareholders will soon vote on an agreement to be acquired by Solexa, whose current CEO, John West, will take over the role of CEO of the combined company after the merger is completed.


The supervisory board of Lion Bioscience, led by former CEO Friedrich von Bohlen, has reappointed the firm’s executive board effective immediately, Lion announced last week. Thure Etzold, former co-CEO, has been named CEO; Peter Willinger, who has been head of the finance department since 1998, was appointed chief financial officer; and Joseph Donahue moves from the board but remains responsible for global sales while also serving as president of Lion’s US subsidiary in Cambridge, Mass.

Following a supervisory board meeting last month, Daniel Keesman, chief operating officer and co-CEO, and Martin Hollenhorst, chief financial officer and co-CEO, resigned. In addition, the company’s entire supervisory board — Jurgen Dormann, Klaus Pohle, and Richard Roy — also stepped down.


BioAdvance, a biotechnology incubator in Pennsylvania, has appointed Michael Pellini to serve as its first entrepreneur-in-residence. Pellini was most recently CEO of Genomics Collaborative, which was acquired by SeraCare Life Sciences in June.


Norrie Russell has been hired by Invitrogen as vice president and general manager of its functional genomics strategic business unit, the company said last week. Most recently, he was president and CEO of Aviva Biosciences. Prior to that, he was president and CEO of Lynx Therapeutics. Russell holds a PhD in physiology from Glasgow University in Scotland.


Björn Ekström has become CEO of Olink Bioscience, a Swedish startup focusing on protein analysis technology. Previously, Ekström was head of R&D at Pyrosequencing. He also held several positions within R&D at Amersham Biosciences and Pharmacia Biotech.


Tim Germann has assumed the newly created position of vice president of sales and marketing for US Genomics, the company said. Previously he was the northeast sales manager for Affymetrix. Before that, he held sales or management positions at Stratagene, Genometrix, Incyte Genomics, and Molecular Devices.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.